IDEAYA’s Darovasertib Pivotal Trial Succeeds, NDA Underway

What happened

IDEAYA announced that the registrational OptimUM-02 trial of darovasertib plus crizotinib in metastatic uveal melanoma met its primary endpoint, clearing a path for an NDA submission under the FDA’s real-time oncology review program expected to complete in H2 2026. The company also disclosed new clinical collaborations, including a Roche-partnered Phase 1 combination of IDE892 with a pan-RAS inhibitor in MTAP-deleted, RAS-mutant pancreatic cancer, and upcoming ESMO presentations for darovasertib and IDE849. With $1.24 billion in cash and a runway into 2030, IDEAYA is well-capitalized to fund these programs and potential commercialization. However, investors should note that detailed efficacy and safety data from OptimUM-02 have not yet been released, and the competitive landscape for darovasertib and its synthetic‑lethality pipeline remains intense. The positive readout transforms the investment narrative, but execution on regulatory, manufacturing, and commercial fronts will determine ultimate value.

Implication

The OptimUM-02 success and accelerated regulatory path significantly lower the probability of darovasertib failing, shifting the investment case from a binary event to a pre-commercialization setup. With cash runway extended and multiple pipeline catalysts ahead—including ESMO updates and a pancreatic cancer combination—the risk/reward now favors upside potential. However, the true clinical benefit and differentiation of darovasertib versus existing therapies like Kimmtrak will only become clear once full data are published, likely at ESMO. Commercial readiness, partner dynamics, and the ability to advance synthetic‑lethality programs in a competitive field will determine whether the stock can sustain a premium valuation. Given the major uncertainty resolution, upgrading from WAIT to POTENTIAL BUY is appropriate, with conviction dependent on forthcoming detailed data.

Thesis delta

The prior WAIT recommendation was predicated on binary darovasertib pivotal data. With the OptimUM-02 trial meeting its primary endpoint and an NDA now under review, the largest uncertainty is resolved. The lead asset is materially de-risked, justifying an upgrade from WAIT to POTENTIAL BUY.